# A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

> **NCT07184086** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 80 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** CagriSema (Cagrilintide B + semaglutide I)
- **BEHAVIORAL:** Low Energy Diet

## Key facts

- **NCT ID:** NCT07184086
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2027-10-12
- **Final completion:** 2027-10-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184086, "A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07184086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*